Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy
Brief Summary: This global, multicenter, open-label, randomized, controlled study evaluated the efficacy and safety of atezolizumab (an anti-programmed death-ligand 1 \[anti-PD-L1\] antibody)compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure with platinum-containing chemotherapy. Participants were randomized 1:1 to receive either docetaxel or atezolizumab. Treatment may continue as long as participants experienced clinical benefit as assessed by the investigator, i.e., in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.


Options:
A: Arm Label: 60 Gy RT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Radiation: 60 Gy RT | Arm Label: 74 Gy RT; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Radiation: 74 Gy RT | Arm Label: 60 Gy RT + Cetuximab; Type: EXPERIMENTAL; Interventions: Biological: Cetuximab, Drug: Carboplatin, Drug: Paclitaxel, Radiation: 60 Gy RT | Arm Label: 74 Gy RT + Cetuximab; Type: EXPERIMENTAL; Interventions: Biological: Cetuximab, Drug: Carboplatin, Drug: Paclitaxel, Radiation: 74 Gy RT | Intervention Type: BIOLOGICAL; Name: Cetuximab; Assigned to Arm(s): 60 Gy RT + Cetuximab, 74 Gy RT + Cetuximab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 60 Gy RT, 60 Gy RT + Cetuximab, 74 Gy RT, 74 Gy RT + Cetuximab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 60 Gy RT, 60 Gy RT + Cetuximab, 74 Gy RT, 74 Gy RT + Cetuximab | Intervention Type: RADIATION; Name: 60 Gy RT; Assigned to Arm(s): 60 Gy RT, 60 Gy RT + Cetuximab | Intervention Type: RADIATION; Name: 74 Gy RT; Assigned to Arm(s): 74 Gy RT, 74 Gy RT + Cetuximab
B: Arm Label: Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Arm Label: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Docetaxel
C: Arm Label: GSK 249553 Group; Type: EXPERIMENTAL; Interventions: Biological: GSK 249553 vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: GSK 249553 vaccine; Assigned to Arm(s): GSK 249553 Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
D: Arm Label: Investigational Arm; Type: EXPERIMENTAL; Interventions: Biological: Tecemotide, Drug: Single low dose cyclophosphamide, Other: Best Supportive Care (BSC) | Arm Label: Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Other: Saline, Other: Best Supportive Care (BSC) | Intervention Type: BIOLOGICAL; Name: Tecemotide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Single low dose cyclophosphamide; Assigned to Arm(s): Investigational Arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Saline; Assigned to Arm(s): Control Arm | Intervention Type: OTHER; Name: Best Supportive Care (BSC); Assigned to Arm(s): Control Arm, Investigational Arm

Answer: B